A web-application that extends functionality of medical device for tumor treatment by means of electrochemotherapy

In the cooperation with the European partners, the medical device called CliniporatorTM (IGEA s.r.l., Carpi, Italy) was developed, in the frame of the Cliniporator project (2000-03) funded by European Community. This device was designed for controlled in vivo cell permeabilization by electroporation. Electroporation is used to provide access to molecules distributed freely in the vascular and extracellular compartments that normally do not enter the intracellular compartments.1,2,3 This technique is already used clinically to deliver cytotoxic molecules like bleomycin and cisplatin to solid tumors by electrochemotherapy (ECT).4,5 For a successful cell electroporation a voltage applied for a given electrode tissue geometry, pulse duration and number of pulses should always be in the range between reversible and irreversible threshold value. If the voltage applied exceeds the irreversible threshold value, a change in a cell membrane becomes permanent and destroys the cell. The most commonly very short (100 μs) highvoltage pulse or a sequence of such pulses are delivered. Pulses are generated in the highvoltage generator of CliniporatorTM and delivRadiol Oncol 2004; 38(1): 49-54.